Alpha 2.0
Login Register
» Authors » Kenji Tsushima

Kenji Tsushima

Explore the profile of Kenji Tsushima including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 151
Citations 1658
Followers 0
Related Specialties
Pulmonary Medicine
General Medicine
Oncology
Top 10 Co-Authors
Keishi Kubo
Tomonobu Koizumi
Koichiro Tatsumi
Jiro Terada
Masanori Yasuo
Mitsuhiro Abe
Yoshitaka Yamazaki
Keisaku Fujimoto
Masayuki Hanaoka
Yuji Tada
Published In
Intern Med
Respirology
Respir Med
Nihon Kokyuki Gakkai Zasshi
Pulm Pharmacol Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review
Aoshiba N, Toriyama K, Yamashita S, Shioiri N, Iwata Y, Uruma T, et al.
Respir Med Case Rep . 2024 Dec; 52:102141. PMID: 39654607
We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and,...
2.
Usefulness of Combined Measurement of Surfactant Protein D, Thrombin-Antithrombin III Complex, D-Dimer, and Plasmin-α2 Plasmin Inhibitor Complex in Acute Exacerbation of Interstitial Lung Disease: A Retrospective Cohort Study
Takeshita Y, To M, Kurosawa Y, Furusho N, Kinouchi T, Tsushima K, et al.
J Clin Med . 2024 Apr; 13(8). PMID: 38673700
: The coagulation cascade due to tissue damage is considered to be one of the causes of poor prognostic outcomes in patients with acute exacerbations of interstitial lung disease (AE-ILD)....
3.
Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases
Sun Y, Saito K, Ushiki A, Abe M, Saito Y, Kashiwada T, et al.
Respir Res . 2024 Jan; 25(1):31. PMID: 38221627
Background: Drug-induced interstitial lung disease (DILD) is a lung injury caused by various types of drugs and is a serious problem in both clinical practice and drug development. Clinical management...
4.
Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19
Iwata S, Kobayashi O, Kurashima K, Doi Y, Kunishima H, Shinkai M, et al.
J Infect Chemother . 2023 Oct; 30(3):219-227. PMID: 37832822
Introduction: Favipiravir terminates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Accordingly, early administration of favipiravir to SARS-CoV-2-infected coronavirus disease 2019 (COVID-19) patients may be expected to suppress disease progression....
5.
Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial
Shimasaki S, Baba T, Ogura T, Akasaka K, Matsushima H, Izumi S, et al.
Infect Dis (Lond) . 2023 Sep; 55(12):857-873. PMID: 37729076
Background: Granulocyte-macrophage colony stimulating factor (GM-CSF) inhalation may alleviate pulmonary inflammation caused by viral pneumonia. To investigate this, we evaluated its efficacy on COVID-19 pneumonia. Methods: This double-blind, randomised, placebo-controlled...
6.
The National Early Warning Score on admission predicts severe disease and in-hospital mortality of the coronavirus disease 2019 Delta variant: A retrospective cohort study
Endo T, Khoujah D, Motohashi T, Shinozaki T, Tsushima K, Fujitani S, et al.
Acute Med Surg . 2023 Jun; 10(1):e851. PMID: 37261374
Background: Clinical risk scores are widely used in emergency medicine, and some studies have evaluated their use in patients with coronavirus disease 2019 (COVID-19). However, no studies have evaluated their...
7.
Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
Umeda A, Shimada H, Yamane T, Mochizuki T, Inoue Y, Tsushima K, et al.
Front Physiol . 2023 May; 14:1131949. PMID: 37179838
The Japanese drug use system allowed the once-daily use of inhaled corticosteroid fluticasone furoate (FF) combined with a long-acting beta-2 agonist vilanterol (VI) and a long-acting muscarinic antagonist umeclidinium (UMEC)...
8.
Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan
Hirasawa Y, Terada J, Shionoya Y, Fujikawa A, Isaka Y, Takeshita Y, et al.
Respir Investig . 2023 Apr; 61(4):438-444. PMID: 37119744
Background: Dexamethasone, remdesivir, and baricitinib reduce mortality in patients with coronavirus disease 2019 (COVID-19). A single-arm study using combination therapy with all three drugs reported low mortality in patients with...
9.
A case of bunashimeji mushroom-induced hypersensitivity pneumonitis diagnosed by inhalational provocation test in a hospital room
Akagami T, Nakagome K, Takagi S, Yamazaki S, Minezaki S, Nakamura H, et al.
Respirol Case Rep . 2023 Apr; 11(5):e01134. PMID: 37032708
A 66-year-old woman was admitted to our hospital with a 2-month history of dry cough and exertional dyspnea. She had worked as a mushroom farmer and had been exposed to...
10.
Relationship between Anti-SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen following COVID-19 Vaccination
Takeshita Y, To Y, Kurosawa Y, Kinouchi T, Tsuya K, Tada Y, et al.
Immunohorizons . 2023 Jan; 7(1):97-105. PMID: 36645852
Although the effectiveness of vaccination at preventing hospitalization and severe coronavirus disease (COVID-19) has been reported in numerous studies, the detailed mechanism of innate immunity occurring in host cells by...